Literature DB >> 761446

Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

L B Sheiner, D R Stanski, S Vozeh, R D Miller, J Ham.   

Abstract

We propose a model of drug pharmacodynamic response that when integrated with a pharmacokinetic model allows characterization of the temporal aspects of pharmacodynamics as well as the time-independent sensitivity component. The total model can accommodate extremes of effect. It allows fitting of simultaneous plasma concentration (Cp) and effect data from the initial distribution phase of drug administration, or from any non-equilibrium phase. The model postulates a hypothetical effect compartment, the dynamics of which are adjusted to reflect the temporal dynamics of drug effect. The effect compartment is modeled as an additional compartment linked to the plasma compartment by a first-order process, but whose exponential does not enter into the pharmacokinetic solution for the mass of drug in the body. The hypothetical amount of drug in the effect compartment is then related to the observed effect by the Hill equation, a nonlinear sigmoid form. Nonlinear least-squares data fitting is used for parameter estimation. The model is demonstrated on two different sets of Cp and effect data for the drug d-tubocurarine (dTC). In 7 normal subjects, the (mean +/- SD) rate constant for equilibration of dTC effect (paralysis) and Cp is 0.13 +/- 0.04 min-1 and the (mean +/- SD) steady-state Cp required to produce 50% paralysis is 0.37 +/- 0.05 microgram/ml.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 761446     DOI: 10.1002/cpt1979253358

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  326 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

2.  Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life.

Authors:  J Laurin; F Donati; F Nekka; F Varin
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-02       Impact factor: 2.745

3.  Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

4.  Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.

Authors:  R Gieschke; J L Steimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jan-Mar       Impact factor: 2.441

5.  Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.

Authors:  J Laurin; F Nekka; F Donati; F Varin
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

6.  Basic pharmacodynamic models for agents that alter production of natural cells.

Authors:  W Krzyzanski; R Ramakrishnan; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

7.  Chemical substance kinetics in the case of chronobiological variations of elimination rate.

Authors:  G Merabet-Atmani; S Aliguechi-Bouhadja; A Redouane; T Filali; K Mansour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Oct-Dec       Impact factor: 2.441

8.  Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels.

Authors:  A Cleton; B A Altorf; R A Voskuyl; M Danhof
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 9.  Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.

Authors:  J V Gobburu; P J Marroum
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling.

Authors:  M R Bouw; R Xie; K Tunblad; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.